Skip to main content
. Author manuscript; available in PMC: 2014 May 22.
Published in final edited form as: Curr Cancer Drug Targets. 2012 Jun;12(5):522–530. doi: 10.2174/156800912800673248

Fig. 1. Lenalidomide.

Fig. 1

Kaplan-Meier survival curves. (A) Kaplan-Meier curves for OS and PFS in all patients who received at least one dose of lenalidomide (N = 33). Median OS estimated at 4 months (95% CI, 3–9 months), and median PFS estimated at 2 months (95% CI, 2–3 months). (B) Kaplan-Meier curves for relapse-free survival in patients who obtained a CR/CRi (n = 10). Median relapse-free survival for the CR/CRi patients was 10 months (95% CI, 2-NE(Fehniger T A et al. Blood 2011;117:1828–1833)